Advanced Androgen-Dependent Carcinoma Of The Prostate

News Advanced Androgen-Dependent Carcinoma Of The Prostate

• Prostate cancer: New predictive and therapeutic options with TRAIL

  One of the human body's protective mechanisms initiated by the TRAIL protein is massively altered in prostate cancer cells - yet the same protein seems to improve the survival prospects of patients. These outstanding results of a cooperative venture between the Clinical Program on Urological Tumours more

• Denosumab Demonstrated Superiority Over Zometa in Delay of Complications Due to Bone Metastases in Advanced Prostate Cancer

  Amgen announced detailed results from a Phase 3, head-to-head trial which compared the efficacy and safety of denosumab versus Zometa(R) (zoledronic acid) in 1,901 patients with hormone-refractory prostate cancer and bone metastases. The study met its primary and secondary endpoints and demonstrate more

• Algeta and IFE agree to collaborate for the manufacture and supply of Alpharadin for future commercial use and clinical trials

  Algeta ASA and the Institute for Energy Technology (IFE) have agreed to collaborate for the manufacture and supply of Alpharadin for future commercial use and clinical trials. No financial terms are disclosed. Alpharadin is a first-in-class, highly targeted alpha-pharmaceutical under clinical eval more

Publications Advanced Androgen-Dependent Carcinoma Of The Prostate

• The current and future role of sequence-based analysis in prostate cancer treatment

  Prostate cancer is the most commonly diagnosed, nondermatologic malignancy in US men. Localized disease can be managed through active surveillance or curative, locally directed therapies, but 30% of men treated with surgery or radiation will need additional (often systemic) treatment for relapsed di more

• An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer

  Androgen deprivation therapy remains the mainstay of medical treatment for advanced prostate cancer. Commonly, this is achieved with medical androgen deprivation rather than surgical intervention as the permanence and psychological effects of the latter are unacceptable for most patients. Degarelix more

• Cost–effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer

  Degarelix, approved in the USA in 2008, is a gonadotropin-releasing hormone antagonist, representing one of the latest additions to androgen deprivation therapy (ADT). ADT is used as first-line therapy for locally advanced or metastatic prostate cancer with the aim to reduce testosterone to castrate more

Market studies Advanced Androgen-Dependent Carcinoma Of The Prostate

• Endothelin A Receptor Antagonist (atrasentan) Fails to Demonstrate an Advantage in the Treatment of Advanced Prostate Cancer

  Introduction This year another endothelin A receptor antagonist failed to demonstrate an advantage for advanced prostate cancer. With the failure of atrasentan in Phase III followed by the failure of two Phase III trials of zibotentan, there is only one trial left which is exploring an endothelin a more

Websites Advanced Androgen-Dependent Carcinoma Of The Prostate